Pharmacyclics® Announces Updated Results For BTK Inhibitor Ibrutinib (PCI-32765) At American Society Of Hematology (ASH) Annual Meeting

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) and its collaborators provided clinical and pre-clinical presentations on ibrutinib and ibrutinib combinations at the 2012 ASH Annual Meeting. Ibrutinib inhibits Bruton's tyrosine kinase (BTK), which is known to be expressed in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and multiple myeloma (MM). All ASH presentations can be found on the corporate website in the investor relations section. 

"This meeting at ASH has been filled with exciting validations of ibrutinib and its potential in blood cancers.  We are concluding ASH with 9 poster presentations and 9 oral presentations, of which two were included in the 'ASH Annual Press Program' and both were honored as a 'Best of ASH'," said Bob Duggan, CEO and chairman of Pharmacyclics. "We are very proud of these clinical and research accomplishments and I would like to thank all our investigators and employees for their support and continued efforts in developing this compound for patients in need. Together with our partner Janssen we have now successfully entered several pivotal Phase III trial programs and are broadly developing ibrutinib in a multitude of hematologic cancer settings. The results we have shown over the past couple of days have been very encouraging, demonstrate our commitment to a comprehensive program and we are looking forward to further emerging data in the coming year."

Recent Developments & Highlights

Chronic Lymphocytic Leukemia

At the 2012 ASH Annual Meeting Pharmacyclics and its investigators presented six oral presentations and three posters describing the recent clinical trials and further insights into the mechanism of action of ibrutinib in CLL/SLL patients. These presentations are available for investor review on the company's website. The following summarizes two oral presentations showing recent trial results.

1 2 3 4 5 6 7 Next › Last »